



Survey report MQ 2017-1 U3 Drugs of abuse

Amphetamine

	Target value	Participant	Conform	Conform%
Architect	Negative	1	1	100
Roche Cobas	Negative	3	3	100
Triage 8	Negative	8	8	100
Syva Rapid Test	Negative	2	2	100
Intex	Negative	5	5	100
Syntron Quik	Negative	1	1	100
Triage TOX	Negative	12	12	100
Other quantitativ	Negative	14	14	100
Other Rapid tests	Negative	52	52	100
TOTAL		98	98	100

Methamphetamine

	Target value	Participant	Conform	Conform%
Intex	Negative	2	2	100
Syva Rapid Test	Negative	4	4	100
Triage TOX	Negative	12	12	100
Other Rapid tests	Negative	25	25	100
TOTAL		43	43	100

Ecstasy pos/neg

	Target value	Participant	Conform	Conform%
Other Rapid tests	Negative	16	16	100

Barbiturate

600 µg/l Secobarbital

	Target value	Participant	Conform	Conform%
Architect	Positive	1	1	100
Cobas	Positive	3	3	100
Triage 8	Positive	8	8	100
Intex	Positive	1	1	100
Triage TOX	Positive	12	12	100
Other quantitativ	Positive	10	10	100
Other Rapid tests	Positive	25	24	96
TOTAL		60	59	98

Benzodiazepine

	Target value	Participant	Conform	Conform%
Architect	Negative	1	1	100
Cobas	Negative	4	4	100
Triage 8	Negative	8	8	100
Syva Rapid Test	Negative	1	1	100
Intex	Negative	10	10	100
Syntron Quik	Negative	1	1	100
Triage TOX	Negative	12	12	100
Other quantitativ	Negative	15	15	100
Other Rapid tests	Negative	58	58	100
TOTAL		110	110	100

Cannabinoide

	Target value	Participant	Conform	Conform%
Architect	Negative	1	1	100
Cobas	Negative	4	4	100
Triage 8	Negative	8	8	100
Syva Rapid Test	Negative	7	7	100
Intex	Negative	11	11	100
Syntron Quik	Negative	1	1	100
Triage TOX	Negative	12	12	100
Other quantitativ	Negative	17	17	100
Other Rapid tests	Negative	63	62	98
TOTAL		124	123	99

Cocain

	Target value	Participant	Conform	Conform%
Architect	Negative	1	1	100
Cobas	Negative	4	4	100
Triage 8	Negative	8	8	100
Syva Rapid Test	Negative	6	6	100
Intex	Negative	8	8	100
Syntron Quik	Negative	1	1	100
Triage TOX	Negative	12	12	100
Other quantitativ	Negative	16	16	100
Other Rapid tests	Negative	62	62	100
TOTAL		118	118	100

Methadon

	Target value	Participant	Conform	Conform%
Architect	Negative	1	1	100
Cobas	Negative	4	4	100
Triage 8	Negative	8	8	100
Intex	Negative	10	10	100
Syntron Quik	Negative	1	1	100
Triage TOX	Negative	12	12	100
Other quantitativ	Negative	15	15	100
Other Rapid tests	Negative	50	50	100
TOTAL		101	101	100

EDDP

	Target value	Participant	Conform	Conform%
All	Negative	1	1	100

Methaqualon*600 µg/l Methaqualon*

	Target value	Participant	Conform	Conform%
All	Positive	1	1	100

Opiate

	Target value	Participant	Conform	Conform%
Architect	Negative	1	1	100
Cobas	Negative	4	4	100
Triage 8	Negative	8	8	100
Syva Rapid Test	Negative	6	6	100
Intex	Negative	11	11	100
Syntron Quik	Negative	1	1	100
Triage TOX	Negative	12	12	100
Other quantitativ	Negative	17	17	100
Other Rapid tests	Negative	60	60	100
TOTAL		120	120	100

6-Acetylmorphin

	Target value	Participant	Conform	Conform%
All	Negative	2	2	100

Paracetamol*4000 µg/l Paracetamol*

	Target value	Participant	Conform	Conform%
Triage TOX	Pos/Neg	11	11	100

Phencyclidin

	Target value	Participant	Conform	Conform%
Triage TOX	Negative	12	12	100
Other Rapid tests	Negative	8	8	100
TOTAL		20	20	100

Tricyclic Antidepressiva

	Target value	Participant	Conform	Conform%
Triage 8	Negative	7	7	100
Triage TOX	Negative	12	12	100
All methods	Negative	15	15	100
TOTAL		34	34	100

LSD*2.5 µg/l LSD*

	Target value	Participant	Conform	Conform%
All	Positive	1	1	100

Zürich, 29.3.2017
Dr. R. Fried